Expand embryonic stem cell research.

Dear Mr. President:

We write to urge you to expand the current federal policy concerning embryonic stem cell research.

Embryonic stem cells have the potential to be used to treat and better understand deadly and disabling diseases and conditions that affect more than 100 million Americans, such as cancer, heart disease, diabetes, Parkinson's, Alzheimer's, multiple sclerosis, spinal cord injury, and many others.

We appreciate your words of support for the enormous potential of this research, and we know that you intended your policy to help promote this research to its fullest. As you know, the Administration's policy limits federal funding only to embryonic stem cells that were derived by August 9, 2001.

However, scientists have told us that since the policy went into effect more than two years ago, we have learned that the embryonic stem cell lines eligible for federal funding will not be suitable to effectively promote this research. We therefore feel it is essential to relax the restrictions in the current policy for this research to be fully explored.

Among the difficult challenges with the current policy are the following:

• While it originally appeared that 78 embryonic stem cell lines would be available for research, only 19 are available to researchers.
• All available stem cell lines are contaminated with mouse feeder cells, making their therapeutic use for humans uncertain.
• It is increasingly difficult to attract new scientists to this area of research because of concerns that funding restrictions will keep this research from being successful.
• Despite the fact that U.S. scientists were the first to derive human embryonic stem cells, leadership in this area of research is shifting to other countries.